Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lepper, E. R.
Right arrow Articles by Sparreboom, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lepper, E. R.
Right arrow Articles by Sparreboom, A.
Clinical Cancer Research Vol. 11, 7398-7404, October 15, 2005
© 2005 American Association for Cancer Research

Cancer Therapy: Clinical

Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

Erin R. Lepper1, Sharyn D. Baker5, Matt Permenter2, Nicole Ries5, Ron H.N. van Schaik7, Paul W. Schenk7, Douglas K. Price2, Danielle Ahn2, Nicola F. Smith2, George Cusatis5, Roxann G. Ingersoll6, Susan E. Bates3, Ron H.J. Mathijssen8, Jaap Verweij8, William D. Figg2,4 and Alex Sparreboom4

Authors' Affiliations: 1 Science Applications International Corporation-Frederick, 2 Molecular Pharmacology Section, 3 Cancer Therapeutics Branch, 4 Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland; 5 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 6 Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Departments of 7 Clinical Chemistry, Erasmus MC and 8 Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands

Requests for reprints: Alex Sparreboom, Clinical Pharmacology Research Core, National Cancer Institute, Room 5A01, Building 10, 9000 Rockville Pike, Bethesda, MD 20892. Phone: 301-402-9498; Fax: 301-402-8606; E-mail: SparrebA{at}mail.nih.gov.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe.

Experimental Design: Five variants in CYP3A4 and CYP3A5 were evaluated in 58 patients (21 women and 37 men) receiving a short i.v. bolus of midazolam (dose, 0.0145 or 0.025 mg/kg). Midazolam concentrations in plasma were determined using liquid chromatography-mass spectrometry, and pharmacokinetic variables were calculated using noncompartmental analysis. Genomic DNA was characterized for the variants by PCR-RFLP, and all genotypes were confirmed by direct nucleotide sequencing.

Results: The mean clearance of midazolam was 24.4 ± 9.12 L/h, and phenotypic CYP3A activity varied about 4-fold in this population (range, 10.8-44.3 L/h). There were six carriers of the CYP3A4*1B allele (allele frequency, 0.061). No variant alleles for CYP3A4*17, CYP3A4*18A, or CYP3A5*6 were identified. Forty-eight of the 58 patients were homozygous variant for CYP3A5*3C, eight were heterozygous, and two were homozygous wild type (allele frequency, 0.897). No associations were noted between any of the studied genotypes and the phenotypic measures (P ≥ 0.16). Likewise, a common variant in exon 26 in the gene encoding P-glycoprotein [i.e., ABCB1 (MDR1) 3435C>T] that was previously reported to be linked to CYP3A4 mRNA levels was unrelated to any of the studied phenotypic measures (P ≥ 0.49).

Conclusions. The studied genetic variants in CYP3A4 and CYP3A5 are unlikely to have an important functional significance to phenotypic CYP3A activity in patients with cancer.

Isoforms of the cytochrome P450 (CYP) 3A subfamily are the most abundantly expressed CYP enzymes in the human liver (1). In adults, CYP3A4 and CYP3A5 are predominant among the four known isoforms (CYP3A4, CYP3A5, CYP3A7, and CYP3A43) in the liver and intestines (1). However, metabolically active CYP3A5 is expressed only by an estimated 10% to 30% of Caucasians and 50% to 60% of African Americans (2, 3). The genetic basis for polymorphically expressed CYP3A5 was recently reported to be associated with a single nucleotide polymorphism (SNP) in intron 3 of the CYP3A5 gene (CYP3A5*3C; refs. 4, 5). This SNP causes alternative splicing and truncation of CYP3A5 protein and provides the basis for the absence of CYP3A5 protein in most individuals of Caucasian descent. In people with at least one CYP3A5*1A wild-type allele, CYP3A5 accounts for at least 50% of the total CYP3A content, and results in ~2- to 3-fold higher total CYP3A activity in vitro (4, 6). The most prevalent polymorphism in CYP3A4 (CYP3A4*1B) occurs in the 5' flanking region of the gene. The frequency of this allele ranges from 2% to 9.6% in Caucasians to 35% to 67% in African Americans (1).

A wide variation in CYP3A expression and activity exists in humans, which is reflected by extensive interindividual differences in the clearance of CYP3A substrate drugs and phenotyping probes like midazolam (7). For many anticancer drugs used therapeutically, pharmacokinetic variability is a significant contributor to the variability of both the severity of side effects and therapeutic response (8). Furthermore, the metabolism of 37% of all currently approved cytostatic and/or cytotoxic anticancer agents is known to be mediated, at least in part, by the CYP3A isoforms. Hence, identification of factors affecting the clearance of CYP3A substrates could aid in predicting or adapting appropriate, individualized doses of anticancer drugs. Here, we evaluated the effect of common naturally occurring variants in genes encoding CYP3A4 and CYP3A5 in cancer patients receiving midazolam as a phenotyping probe.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Patient selection. This study was conducted under two Institutional Review Board–approved protocols and all patients signed an informed consent form before treatment. Patients with a histologically or cytologically confirmed diagnosis of malignant solid tumor were eligible for two clinical trials in which patients underwent CYP3A phenotyping with i.v. given midazolam (9, 10). Eligibility criteria included age >18 years; performance status ≤1; and adequate hematopoietic (leukocytes, ≥4.0 x 109/L; neutrophils, ≥1.5 x 109/L; and platelets, ≥100 x 109/L), hepatic (bilirubin within normal limits; transaminases, ≤2 times the upper limit of normal), and renal function (creatinine clearance, ≥50 mL/min). All patients were required to have an estimated life expectancy of >12 weeks and no previous chemotherapy was allowed for at least 4 weeks before enrollment. The patients were asked to abstain from substances known to affect the function and/or expression of CYP3A and/or ABCB1 for a period of 2 weeks before, during, and up to 3 weeks after the administration of midazolam.

Blood sampling and processing. Blood samples were collected in glass tubes containing heparin. Samples were drawn at 5 and 30 minutes and 1, 2, 3, 4, and 5 hours following bolus i.v. administration of midazolam at a dose of either 0.0145 or 0.025 mg/kg. In about half of the patients, additional samples were obtained at 15 minutes and 6 hours after midazolam administration. Immediately after collection, each sample was centrifuged for 10 minutes at 2,000 x g (4°C), and plasma supernatants were stored at –80°C until the day of analysis.

Drug measurement and pharmacokinetic analysis. Quantitation of midazolam in plasma was done by high-performance liquid chromatography with mass spectrometric detection, as described previously (11). Pharmacokinetic profiles of midazolam were analyzed by noncompartmental methods using the software package WinNonlin version 4.0 (Pharsight, Mountain View, CA). The variables calculated included area under the plasma concentration-time curve extrapolated to infinity (AUC), clearance (CL, calculated as dose/AUC), volume of distribution at steady-state (Vss), and half-life of the terminal phase (t1/2, z). The AUC was normalized to a dose of 0.025 mg/kg. As a comparison, the AUC was also calculated based on the limited sampling model described previously (12).

CYP3A4 and CYP3A5 genotype analysis. Plasma was used to isolate genomic DNA according to the manufacturer's instructions using the UltraSens Virus Kit (Qiagen, Valencia, CA). Variations in CYP3A4 (CYP3A4*1B, CYP3A4*17, and CYP3A4*18A) and CYP3A5 (CYP3A5*3C and CYP3A5*6) were analyzed using RFLP-based techniques, as previously described (13, 14). Confirmation of all the variant genotype assignments (i.e., for CYP3A4*1B, CYP3A5*3C, and CYP3A5*6) was done using direct nucleotide sequencing.

In preparation for sequencing, an initial PCR was done with concentrated DNA using 20 pmol of each primer. For CYP3A4*1B, the primers were designed and chosen as follows: 5'-CTGTGTGAGGAGTTTGGTGAG-3' (CYP3A4*1B F3) and 5'-TGGAAGAGGCTTCTCCACCTTG-3' (CYP3A4*1B R3). These primers were added to a reaction mixture of 1x PCR buffer (Perkin-Elmer, Norwalk, CT), 2 mmol/L of each of the four deoxynucleotide triphosphates, 1.5 mmol/L MgCl2, and 2 units of Platinum Taq polymerase (Invitrogen, Carlsbad, CA) in a reaction volume of 20 µL. The temperature profile for the PCR reaction was one cycle at 94°C for 5 minutes followed by 20 cycles of 94°C for 30 seconds, 62°C for 30 seconds, and 72°C for 30 seconds, with a final 7-minute cycle at 72°C. After initial amplification, 3 µL of amplified product were removed and an additional PCR amplification was done using 40 pmol of the primers 5'-GCTCTGTCTGTCTGGGTTTGG-3' (CYP3A4*1B F4) and 5'-CACACCACTCACTGACCTCCT-3' (CYP3A4*1B R4) in a 50-µL reaction. PCR conditions were 94°C for 5 minutes followed by 40 cycles of 94°C for 30 seconds, 64°C for 30 seconds, and 72°C for 30 seconds, with a final 7-minute cycle at 72°C. Sequencing was done using the following primers: (CYP3A4*1B F5) 5'-AGGTGTGGCTTGTTGGGATG-3' for the forward strand and (CYP3A4*1B R5) 5'-TCAGAAACTCAAGTGGAGCC-3' for the reverse strand.

For the CYP3A5*3C allele, primers were designed and chosen as follows: 5'-TCCTCAGAATCCACAGCGCTG-3' (CYP3A5*3C F1) and 5'-TTTATGTGCTGGAGAAGGACG-3' (CYP3A5*3C R1). These primers were used in a 20-µL reaction that contained 1x PCR buffer (Perkin-Elmer), 1.5 mmol/L MgCl2, 2 mmol/L deoxynucleotide triphosphates, and 2 units of Platinum Taq polymerase (Invitrogen). The cycle conditions were: one cycle at 94°C for 5 minutes followed by 20 cycles of 94°C for 30 seconds, 64°C for 30 seconds, and 72°C for 30 seconds, ending with a final 7-minute cycle at 72°C. After initial amplification, 3 µL of amplified product were removed and an additional PCR amplification (as described above in a total of 50 µL final volume) was done using 40 pmol of primers 5'-AGCACTTGATGATTTACCTGCC-3' (CYP3A5*3C F2) and 5'-CCAGGAAGCCAGACTTTGATC-3' (CYP3A5*3C R2). PCR conditions for this reaction were 94°C for 5 minutes followed by 40 cycles of 94°C for 30 seconds, 62°C for 30 seconds, and 72°C for 30 seconds, with a final 7-minute cycle at 72°C. Sequencing primers were as follows: (CYP3A5*3C F3) 5'-AGTGGCATAGGAGATACCCAC-3' and (CYP3A5*3C R3) 5'-AGGTTCTAGTTCATTAGGGTG-3'.

For the CYP3A5*6 allele, an initial PCR was done using the sample DNA and 20 pmol of each primer, 5'-AGGGAGTAGATGGAAGATGATTC-3' (CYP3A5*6 F1) and 5'-AGTTGATTATTGGATGCTTAGGGC-3' (CYP3A5*6 R1). These primers were used in the initial reaction along with 1x PCR buffer (Perkin-Elmer), 1.5 mmol/L MgCl2, 2 mmol/L deoxynucleotide triphosphates, and 2 units of Platinum Taq polymerase (Invitrogen) in a reaction volume of 20 µL. The temperature profile for the PCR reaction was one cycle at 94°C for 5 minutes, 40 cycles of 94°C for 30 seconds, 64°C for 30 seconds, and 72°C for 30 seconds followed by a final 7-minute cycle at 72°C. After initial amplification, 3 µL of amplified product were removed and an additional PCR amplification using the above reaction ingredients was done using 40 pmol of the designed primers 5'-TGCTGCATGTATAGTGGAAGGAC-3' (CYP3A5*6 F2) and 5'-TTTGTGGTGGGGTGTTGACAGC-3' (CYP3A5*6 R2). PCR conditions for this reaction were 94°C for 5 minutes followed by 40 cycles of 94°C for 30 seconds, 66°C for 30 seconds, and 72°C for 30 seconds, with a final 7-minute cycle at 72°C. The sequencing primers were 5'-TTGGGGCCTACAGCATGGATG-3' (CYP3A5*6 F3) and 5'-TGTGTGAGGGCTCTAGATTGAC-3' (CYP3A5*6 R3). The existence of each variant was determined by direct nucleotide sequencing using the dRhodamine Terminator Cycle Sequencing Ready Reaction kit on an ABI 310 genetic analyzer (Applied Biosystems, Foster City, CA). Concordance in results between RFLP and direct sequence analysis was observed in all but one sample (for CYP3A5*3C only); results from sequence analysis were used for correlation with midazolam pharmacokinetic variables.

ABCB1 (MDR1) genotype analysis. The following primers were designed for the ABCB1 3435C>T variant in exon 26: 5'-AGCAACCTTACATCTACTAC-3' (ABCB1 3435C>T 6 F) and 5'-GGAGAGACAGTCATGCCTAC-3' (ABCB1 3435C>T R) and nested primers 5'-TCACAGTAACTTGGCAGTTTCA-3' (ABCB1 3435C>T F) and 5'-GGGACCAGCCCCTTATAAATC-3' (ABCB1 3435C>T R; Invitrogen). The outside primers and ~100 ng of genomic DNA were added to a 15-µL reaction mixture consisting of 1 mmol/L deoxynucleotide triphosphates, 1x PCR buffer, 2.5 mmol/L MgCl2, and 0.6 units of Amplitaq Gold (Applied Biosystems). For the nested PCR reaction, 2 µL of the first PCR product were used as template for amplification. The thermocycler conditions were an initial cycle at 95°C for 12 minutes followed by 10 cycles 94°C for 45 seconds, 55°C for 1 minute and 72°C for 1 minute, 20 cycles of 89°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute, and ending with a final 10-minute cycle at 72°C. The restriction enzyme MboI (New England Biolabs, Beverly, MA) was used for the determination of the variants. Enzyme (0.5 µL) and 2 µL of enzyme buffer were added to 20 µL of PCR product and incubated at 37°C for 1 hour followed by an incubation at 65°C for 20 minutes. Blue juice (1 µL of 5x solution) was added to 10 µL restricted PCR product and run on a 2.0% agarose gel with ethidium bromide as a fluorescence detector. A "T" mutation was determined by bands of 408, 263, 158, 103, and 59 bp; a "C" was determined by bands of 263, 236, 172, 158, and 59 bp; heterozygous samples contained all bands. The existence of the variant was also determined by direct nucleotide sequencing after a cleanup step with MinElute PCR purification kit (Qiagen) in a total volume of 12 µL, which included 6 µL of DNA at 3 ng per 100 bp of amplified products and 6 µL of either the forward or reverse primer. Sequencing in the forward and reverse direction was done using an ABI 3730XL Sequencer (Applied Biosystems). Concordance in results between RFLP and direct sequence analysis was observed in all but four samples; results from sequence analysis were used for correlation with midazolam pharmacokinetic variables.

Statistical considerations. All data are presented as mean values ± SD, unless stated otherwise. Genotype-frequency analysis of Hardy-Weinberg equilibrium was carried out using Clump version 1.9. Linkage disequilibrium was calculated using EMLD (Qiqing Huang; see http://linkage.rockefeller.edu/soft/). The linkage between each pair of SNPs was determined in terms of the classic statistic D'. The absolute value for D' (|D'|) of 1 denotes complete linkage disequilibrium, whereas a value of 0 denotes complete linkage equilibrium.

To relate pharmacokinetic variables with the variant genotypes, the Kruskal-Wallis test, a nonparametric one-way ANOVA, was used for each polymorphism examined. (NCSS v2001; J. Hintze, Number Cruncher Statistical Systems, Kaysville, UT). Although this study was mainly exploratory in intent, a Bonferroni adjustment was used to evaluate the significance of the multiple comparisons. Two-sided Ps < 0.017 (0.05 divided by the three observed variant genotypes) were regarded as statistically significant and Ps < 0.05 were considered a trend. These levels were chosen to reduce the risk of finding purely coincidental associations in view of the number of variant genotypes analyzed concurrently.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Patients. A total of 58 adult patients (21 women and 37 men) were evaluated during this study. Patients were of Caucasian (n = 55), African American (n = 2), or Hispanic (n = 1) descent and were between 29 and 73 years old (median age, 57 years). Additional patient demographics are shown in Table 1.


View this table:
[in this window]
[in a new window]
  		Table 1. Demographic characteristics

 
Midazolam disposition. Complete midazolam pharmacokinetic data following i.v. administration were available in all 58 patients. The mean dose-normalized AUC was 90.2 ± 35.8 ng h/mL, whereas the mean clearance was 24.4 ± 9.12 L/h, which is consistent with earlier findings obtained in cancer patients following i.v. administration of midazolam (15, 16). Table 2 provides a comparison of the clearance values determined in previously conducted trials in cancer patients and healthy volunteers, which involved genotyping for CYP3A5*3C.


View this table:
[in this window]
[in a new window]
  		Table 2. Summary of midazolam pharmacokinetics

 
Variant genotypes. Genotyping results were available for all patients except for CYP3A4*1B, which had available data for 57 of the 58 patients (Table 3). Of these 57 patients, there were six carriers of the CYP3A4*1B allele (five heterozygous CYP3A4*1A/*1B and one homozygous CYP3A4*1B/*1B). Both of the subjects of African American descent were wild type for CYP3A4*1B (homozygous CYP3A4*1A/*1A). No patients were identified carrying variant alleles for CYP3A4*17, CYP3A4*18A, or CYP3A5*6. Forty-eight of the 58 patients were homozygous variants for CYP3A5*3C and there were eight heterozygotes (CYP3A5*1A/*3C). The ABCB1 3435C>T genotypes were distributed as follows: 12 wild type (C/C), 35 heterozygous (C/T), and 11 variant (T/T).


View this table:
[in this window]
[in a new window]
  		Table 3. Genotype and allele frequencies for the studied variants

 
ABCB1 3435C>T was in linkage equilibrium with both CYP3A4*1B and CYP3A5*3C (D' = 0.183 and 0.0933, respectively). Linkage disequilibrium was apparent between CYP3A4*1B and CYP3A5*3C (D' = 0.656), as described previously (17).

Genotype-phenotype relations. There were no significant correlations between any of the variant genotypes and clearance, volume of distribution at steady state, or AUC (Fig. 1; Table 4). Although the mean midazolam clearance was 1.2 times higher in patients with the CYP3A5*1A/*1A genotype compared with patients that were homozygous variant (CYP3A5*3C/*3C), this difference was not statistically significant (P = 0.50). Furthermore, there was no correlation between CYP3A5*3C genotype status and clearance, when patients with the homozygous variant genotype (CYP3A5*3C/*3C) were compared with patients that had at least one wild-type allele (CYP3A5*1A/*1A and CYP3A5*1A/*3C; P = 0.24).



View larger version (12K):
[in this window]
[in a new window]
  		Fig. 1. Midazolam clearance as a function of the CYP3A4*1B, CYP3A5*3C, and ABCB1 3435C>T genotypes. Horizontal lines indicate mean values in each group. Abbreviations: Wt, homozygous wild-type patient; Het, heterozygous patient; Var, homozygous variant patient. Two-sided Ps are given above the panels.

 

View this table:
[in this window]
[in a new window]
  		Table 4. Genotype-phenotype relationships

 
Comparison of predicted and observed area under the plasma concentration-time curve. The AUC of midazolam was also calculated with a limited-sampling model based on the 4-hour time point, as done by Wong et al. (16). This model was designed originally using a different data set, as described elsewhere (12). Figure 2 shows the correlation of the observed AUC with the calculated AUC. The correlation between the predicted AUC and the observed AUC, using all time points, showed an R2 = 0.749. The mean (±SE) bias and precision of the prediction made by the model, determined by calculation of the percentage mean prediction error and the relative root mean squared prediction error, were –18.3 ± 5.82% and 30.2 ± 3.73%, respectively.



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 2. Scatter plot of the observed AUC of midazolam versus the AUC of midazolam calculated based on the observed midazolam concentration at the 4-hour sampling time point (4-h conc.) using the limited-sampling model equation: AUC = 9.91 + 12.2 x [4-h conc.], as described previously (12). The dotted line indicates a linear regression fit, whereas the solid line represents the line of identity.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
Interindividual variability in drug efficacy and toxicity, resulting in unpredictable patient responses, is commonly observed in all therapeutic areas (18). However, these differences are particularly important in the field of cancer therapy because many anticancer agents have a narrow therapeutic index. It is now well recognized that in addition to environmental and physiologic factors, such interpatient variation is commonly associated with polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and/or drug targets. In this study, we tested the hypothesis that the disposition of the prototypical CYP3A substrate drug midazolam in cancer patients is dependent on genetic variability in the CYP3A4 and CYP3A5 genes.

It has been proposed that genotyping for CYP3A4 and CYP3A5 variants may be useful for prediction of total CYP3A activity because of the genetic diversity in the genes encoding these proteins (2, 3). Over 30 SNPs in CYP3A4 have been published; however, most are unlikely to contribute substantially to the interindividual variability of CYP3A4 activity in vivo, based on their limited functional significance and/or low allele frequency (3, 19, 20). Similar to earlier findings (21), the very low allele frequency of the functional CYP3A4*17 and CYP3A4*18A variants evaluated in the present study suggests that these SNPs most likely have no broad relevance to CYP3A4 activity and function in predominantly Caucasian populations. The one additional SNP that was studied here, CYP3A4*1B, is a promoter variant in the so-called nifedipine-specific element. The allele frequency of this variant is known to depend on racial ancestry, being absent in Japanese and Chinese subjects, and present in 2% to 10% in Caucasians and 35% to 67% in African Americans, respectively (3). The currently observed frequency of 6.1% is consistent with previous estimates for predominantly Caucasian populations. Although the functional significance of this SNP presently remains unclear, the preponderance of the evidence suggests that CYP3A4*1B does not affect the metabolism and clearance of CYP3A4 substrate drugs (22–26). Likewise, in the current study, the pharmacokinetic profile of midazolam was not significantly different between patients with or without the CYP3A4*1B variant allele.

As mentioned previously and in contrast to CYP3A4, the CYP3A5 protein isoform is known to be expressed in only a small percentage of Caucasian individuals and this has been linked to a common transition in intron 3 of the CYP3A5 gene (CYP3A5*3C), which introduces a frameshift during translation and results in a truncated, nonfunctional protein (4, 5). Approximately 70% to 90% of Caucasian subjects are homozygous variant for CYP3A5*3C and thus are deficient in functionally active CYP3A5 (27), which is consistent with the currently observed genotype frequency of 89.7%. In the present study, no change in midazolam pharmacokinetic variables was noted between 10 patients with at least one wild-type (CYP3A5*1A) allele and 48 patients carrying two variant (CYP3A5*3C) alleles. This is similar to findings obtained in healthy subjects using midazolam (24, 25, 28, 29), or various other CYP3A phenotyping probes, including erythromycin (23, 25) and nifedipine (30). Interestingly, in a small cohort of Australian cancer patients, Wong et al. recently observed ~1.4-fold higher systemic clearance of midazolam in four patients with the CYP3A5*1A/*3C genotype compared with 39 patients with the CYP3A5*3C/*3C genotype (P = 0.01; ref. 16). In an effort to explain this discrepant finding, it is noteworthy that the interindividual variability in CYP3A phenotypic activity was substantially greater in the study reported by Wong et al. than that found in the various other studies [8-fold for systemic clearance and 24-fold for apparent oral clearance (16) versus 3.3- to 5.2-fold (24, 25, 28, 29)], suggesting the possibility of altered expression of either CYP3A4, CYP3A5, or both as a result of differences in advancement of the disease state of patients in the studied cohort (31).

Wong et al. estimated the systemic midazolam clearance from a previously developed limited-sampling model based on the collection of one plasma sample obtained 4 hours after drug administration (16). Although a retrospective validation of this model on our own data set indicated a good correlation between the predicted AUC and the observed AUC (R2 = 0.749), the model had a statistically significant tendency for systematic negative error and showed poor precision. To illustrate this problem, two different patients in our cohort that had very similar observed AUC values of 117.0 and 117.2 ng h/mL, respectively, had a predicted AUC based on the limited-sampling model of 37.3 and 165 ng h/mL, respectively. This raises the possibility that some of the proposed genotype-phenotype associations described previously that were based on variable estimates from a limited-sampling model might be particularly prone to the risk of false-positive error due to inaccurate phenotypic assessments. In addition, some error may also be attributed to the smaller sample size used in the previous study (16). Collectively, current evidence does not suggest that CYP3A5*3C-associated differences in the extent of drug metabolism of CYP3A substrates are clinically important.

The extent to which the CYP3A isoforms metabolize midazolam is likely to be determined, at least in part, by intracellular drug concentrations in the liver and, to a lesser extent, the intestine. This process, in turn, is partially dependent on the ATP-binding cassette transporters like ABCB1 (P-glycoprotein) that are localized in the apical membrane of hepatocytes and enterocytes. Although it has been suggested that midazolam is not a substrate for ABCB1 (32), recent data have indicated that midazolam exhibits characteristics of a highly permeable ABCB1 substrate (33). The clearance of midazolam has also been shown to be correlated (r = 0.6; P = 0.0005) with the clearance of docetaxel (15), a known dual substrate of CYP3A and ABCB1 (34), suggesting that varying expression of ABCB1 may alter midazolam clearance. In recent years, various genetic variants in the ABCB1 gene have been described that may effect transporter expression or function (35). The most extensively studied ABCB1 variant to date is a common synonymous C-to-T transition at nucleotide position 3435 at a wobble position in exon 26 (36). Although this transition does not change its encoded amino acid, recent findings have indicated that this variant is associated with altered protein expression in different human tissues (37), and this may result in decreased hepatobiliary and/or intestinal secretion of substrate drugs. Furthermore, a reduced expression of intestinal CYP3A4 mRNA has been observed in subjects carrying the homozygous variant genotype of the ABCB1 3435C>T polymorphism in a Japanese population (38), further pointing to the possibility of ABCB1 genotype affecting midazolam clearance. However, in this study, midazolam pharmacokinetic variables were not significantly influenced by the ABCB1 3435C>T genotype, which is consistent with prior observations in healthy volunteers (25, 39). It should be noted that the lack of relationships with this SNP is, as expected, consistent with preclinical observations in Abcb1a-deficient mice that metabolism rather than transport is the prominent elimination pathway for midazolam (40). This further suggests that the involvement of ABCB1 in the disposition of midazolam may be relatively unimportant regardless of ABCB1 genotype status.

The lack of statistically significant relations in this study does not necessarily mean that there are none, especially in light of the few individuals studied in our population with a homozygous variant genotype. However, the variant genotype effects are minor and/or the genotype heterogeneity is sufficiently small to conclude that the presently studied variants in the CYP3A4 and CYP3A5 genes do not cause a substantial interindividual difference in midazolam clearance and thus are unlikely to have an important functional significance in cancer patients treated with CYP3A substrate drugs. For example, even in a population of this size, if CYP3A5 genotype accounted for the large degree of variability in midazolam pharmacokinetics, detection of this effect would have been expected.

There may be a number of other factors contributing to the variability in midazolam pharmacokinetics, because the tested genetic variants do not seem to explain this finding. A recent study has shown an inverse correlation between liver dysfunction, particularly total bilirubin levels, and CYP3A activity (23). Although all participants in the current study had total bilirubin levels within 1.5 times the upper limit of normal, there was still a considerable range represented (Table 1). Inflammatory response in patients with cancer, resulting in increased {alpha}-1 acid glycoprotein serum concentrations, has also been suggested to decrease clearance by the CYP3A isozymes (41). Age and sex have also been postulated to influence CYP3A activity. Furthermore, many drugs and herbal medications are known to interact with CYP3A. Although patients were asked to abstain from any drugs known to affect the function and/or expression of either CYP3A or ABCB1, this possibility cannot be entirely excluded. Finally, it is possible that additional genes, genetic variants and/or haplotypes of importance to the pharmacokinetics of CYP3A substrate drugs like midazolam may yet be discovered and/or evaluated. Further investigation is needed to determine the relative role of genetic variation and environmental variables (e.g., concomitant drugs or herbs) on the pharmacokinetics of anticancer drugs that are substrates of CYP3A4 and CYP3A5.


   Acknowledgments
 
We thank Marloes van der Werf and Ilse van der Heiden (Department of Clinical Chemistry, Erasmus MC, Rotterdam, the Netherlands) for expert technical assistance and Dr. Seth M. Steinberg (Center for Cancer Research, Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD) for critical review of the article.


   Footnotes
 
Grant support: National Cancer Institute contract N01-CO-12400 (E.R. Lepper) and the Cornelis Vrolijk Development Fund, IJmuiden, the Netherlands (J. Verweij).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Disclaimer: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government.

Received 3/ 9/05; revised 5/10/05; accepted 5/18/05.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271–94.[CrossRef][Medline]
  2. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004;26:192–9.[CrossRef][Medline]
  3. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243–72.[CrossRef][Medline]
  4. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383–91.[CrossRef][Medline]
  5. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773–9.[CrossRef][Medline]
  6. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62:162–72.[Abstract/Free Full Text]
  7. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485–505.[CrossRef][Medline]
  8. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538–49.[Free Full Text]
  9. Bates SE, Bakke S, Kang M, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 2004;10:4724–33.[Abstract/Free Full Text]
  10. Mathijssen RH, de Jong FA, van Schaik RH, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004;96:1585–92.[Abstract/Free Full Text]
  11. Lepper ER, Hicks JK, Verweij J, Zhai S, Figg WD, Sparreboom A. Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004;806:305–10.[Medline]
  12. Kim JS, Nafziger AN, Tsunoda SM, et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol 2002;42:376–82.[Abstract]
  13. van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. The CYP3A4*3 allele: is it really rare? Clin Chem 2001;47:1104–6.[Free Full Text]
  14. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002;48:1668–71.[Abstract/Free Full Text]
  15. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683–90.[Abstract/Free Full Text]
  16. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004;75:529–38.[CrossRef][Medline]
  17. Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004;23:100.[CrossRef][Medline]
  18. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464–8.[CrossRef][Medline]
  19. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299:825–31.[Abstract/Free Full Text]
  20. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001;11:447–58.[CrossRef][Medline]
  21. Lee SJ, Bell DA, Coulter S, Ghanayem B, Goldstein JA. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3 representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 2005;313:301–9.
  22. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288–94.[CrossRef][Medline]
  23. Baker SD, van Schaik RH, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004;10:8341–50.[Abstract/Free Full Text]
  24. Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004;60:231–6.[Medline]
  25. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003;13:595–606.[CrossRef][Medline]
  26. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82–91.[CrossRef][Medline]
  27. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003;13:461–72.[CrossRef][Medline]
  28. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002;30:1491–6.[Abstract/Free Full Text]
  29. Yu KS, Cho JY, Jang IJ, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004;76:104–12.[CrossRef][Medline]
  30. Fukuda T, Onishi S, Fukuen S, et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004;4:34–9.[CrossRef][Medline]
  31. Wilkinson GR. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. Clin Pharmacol Ther 2004;76:99–103.[Medline]
  32. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998;358:289–94.[CrossRef][Medline]
  33. Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 2003;20:757–64.[CrossRef][Medline]
  34. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 1993;268:14991–7.[Abstract/Free Full Text]
  35. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13–33.[CrossRef][Medline]
  36. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473–8.[Abstract/Free Full Text]
  37. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003;6:71–84.[CrossRef][Medline]
  38. Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002;12:451–7.[CrossRef][Medline]
  39. Eap CB, Fellay J, Buclin T, et al. CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics 2004;14:255–60.[CrossRef][Medline]
  40. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408–14.[CrossRef][Medline]
  41. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4:224–32.[CrossRef][Medline]
  42. Lee HS, Goh BC, Fan L, et al. Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. Br J Clin Pharmacol 2003;55:270–7.[Medline]



This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
E. T. Morgan, K. B. Goralski, M. Piquette-Miller, K. W. Renton, G. R. Robertson, M. R. Chaluvadi, K. A. Charles, S. J. Clarke, M. Kacevska, C. Liddle, et al.
Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer
Drug Metab. Dispos., February 1, 2008; 36(2): 205 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-S. Tham, N. H.G. Holford, S.-Y. Hor, T. Tan, L. Wang, R.-C. Lim, H.-S. Lee, S.-C. Lee, and B.-C. Goh
Lack of Association of Single-Nucleotide Polymorphisms in Pregnane X Receptor, Hepatic Nuclear Factor 4{alpha}, and Constitutive Androstane Receptor with Docetaxel Pharmacokinetics
Clin. Cancer Res., December 1, 2007; 13(23): 7126 - 7132.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. K. Engels, F. A. de Jong, A. Sparreboom, R. A. A. Mathot, W. J. Loos, J. J. E. M. Kitzen, P. de Bruijn, J. Verweij, and R. H. J. Mathijssen
Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel
Oncologist, March 1, 2007; 12(3): 291 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Charles, L. P. Rivory, S. L. Brown, C. Liddle, S. J. Clarke, and G. R. Robertson
Transcriptional Repression of Hepatic Cytochrome P450 3A4 Gene in the Presence of Cancer
Clin. Cancer Res., December 15, 2006; 12(24): 7492 - 7497.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Cox, J. Low, J. Lee, J. Walshe, N. Denduluri, A. Berman, M. G. Permenter, W. P. Petros, D. K. Price, W. D. Figg, et al.
Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel
Clin. Cancer Res., August 1, 2006; 12(15): 4636 - 4640.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lepper, E. R.
Right arrow Articles by Sparreboom, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lepper, E. R.
Right arrow Articles by Sparreboom, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online